US EditionPublished • loading... • Updated
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
Summary by contagionlive.com
1 Articles
1 Articles
Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study
Gilead Sciences reported positive phase 3 ARTISTRY-2 results demonstrating that a once-daily single-tablet combination of bictegravir and lenacapavir is statistically noninferior to bictegravir/emtricitabine/tenofovir alafenamide tablets in virologically suppressed adults with HIV. The company plans to file for regulatory submissions for approval.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
